Connected Drug Delivery Devices Market

Global Connected Drug Delivery Devices Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2028: The need to boost patient medication adherence, acceleration of remote digital monitoring, and R&D activities are some of the major factors driving the growth of the Global Connected Drug Delivery Devices Market.

Global Connected Drug Delivery Devices Market is valued at USD 4.63 Billion in 2021 and expected to reach USD 7.99 Billion by 2028 with a CAGR of 50.21% over the forecast period.

Scope-

In residential settings, connected medication delivery devices are smart wireless electronic solutions that facilitate the monitoring of patients and counselling. They are equipped with adherence trackers, sensors, monitoring systems, dosage reminders, and teaching tools that provide real-time feedback and tailored patient care. They are more affordable and more practical than care obtained in a clinic. As a result, integrated drug delivery devices are commonly used in the remote monitoring of individuals suffering from conditions like diabetes, asthma, hypertension, hepatitis C, multiple sclerosis, tuberculosis, chronic obstructive pulmonary disease (COPD), clinically isolated syndrome, and those who have received kidney and liver transplants. The growing patient connectedness and engagement brought on by the Internet of Things' (IoT) increased penetration in the medical device industry is likely to be an opportunity for the industry's development. Moreover, five billion individuals used the internet as of April 2022, accounting for 63.1% of the worldwide people, according to research by "Internet World Stats".

The sales of connected medication delivery systems slightly decreased for medical device makers during the COVID-19 pandemic. The worldwide delivery and sales channel disruption are responsible for the observed decline in sales. Restrictions were put in place during the epidemic, which decreased the rate of illness detection and screening. Along with the failure of the clinical trial on connected medicine delivery systems, pharmaceutical R&D was also affected. Nevertheless, the coronavirus crisis brought into sharp relief the necessity for user-friendly and secure homecare options. A healthcare provider may remotely monitor a patient's medicine with the use of web connection equipment. As a result, these factors helped to lessen the COVID-19 pandemic's negative effects, and the market showed consistent development.

The global Connected Drug Delivery Devices market is segmented based on the device type, technology, application, end-use, and region & country level. Based on device type, the global Connected Drug Delivery Devices market is segmented into connected sensors and integrated devices. By technology, the market is segmented into Bluetooth, near field communication, and service. By applications, the global Connected Drug Delivery Devices market is segmented into respiratory, cardiovascular, anaphylaxis, hormone replacement, diabetes, and others. By end-use, the global Connected Drug Delivery Devices market is segmented into hospital, clinics, homecare, and others.

The regions covered in the global Connected Drug Delivery Devices market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global Connected Drug Delivery Devices is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players-

Some major key players for the global Connected Drug Delivery Devices market report cover prominent players like -

• Novo Nordisk A/S
• Teva Respiratory LLC
• Medtronic
• Phillips-Medisize LLC
• Tandem Diabetes Care Inc.
• Adherium Limited
• Propeller health
• Biocorp
• Ypsomed AG
• Aptar Pharma
• others

Segmentation-

By Device Type:

• Connected Sensors
• Integrated Devices

By Technology:

• Bluetooth
• Near Field Communication
• Service

By Application:

• Respiratory
• Cardiovascular
• Anaphylaxis
• Hormone Replacement
• Diabetes
• Others

By End-Use:

• Hospital
• Clinics
• Homecare
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

The need to boost patient medication adherence, acceleration of remote digital monitoring, and R&D activities are some of the major factors driving the growth of the Global Connected Drug Delivery Devices Market Growth

One of the main factors driving the market is the rise in R&D activity. Due to the strong product offerings of numerous important participants, which is predicted to be commercially released throughout the projection period, it also adds to an exponentially growing rate. For instance, in May 2021, Roche, Glooko Inc., DexCom Inc., and myDiabby Healthcare joined up with Eli Lilly and Company to expand connected solutions for diabetics in countries outside of the United States. The firms' diabetes management systems should work with Lilly's Tempo Pen (on the market in many countries across the world) and Tempo Smart Button (in late-stage development), supporting diabetic patients and fostering market expansion.

Another significant aspect expanding the business's potential is the rising need to improve patient medication compliance. As more patients use integrated medication delivery devices, it will be easier for them to manage their own care, which will help decrease the number of trips to doctors' and hospitals. Connected devices offer effective treatment without the requirement for expensive additional interventions by assisting with proper dose and delivery. These systems also include adherence monitors and reminders, which lessen the patient's effort in adhering to the recommended prescription schedule. Additionally, this may lessen the waste of expensive medicines such as injectable biologics.

Due to the rising need for connected sensors to convert conventional drug delivery systems into networked drug delivery devices without affecting their basic operation, the standalone software and components industry is expanding at a significant pace. Despite the fact that the gadget is disposable, the sensor may still be utilized. In addition, the industry has grown significantly as a consequence of technology advancements and an increase in device connection. HeroTracker Sense, a metered-dose inhaler (MDI) add-on that turns a conventional inhalation into a smart linked medicine delivery device, was introduced by Aptar Pharma in February 2022.

The expansion of this market is projected to be fueled in the future years by the rising prevalence of chronic illnesses such as cardiovascular diseases (CVDs), chronic obstructive pulmonary disease (COPD), diabetes, and others that call for effective management of patient health data. According to the most recent data released by the American Heart Association, at least 48 percent of individuals in the United States suffer from cardiovascular disease.

North America is Expected to Capture a Major Share in the Global Connected Drug Delivery Devices Market

Due to the increased prevalence of chronic illnesses and the existence of a sizable target population, North America is predicted to be the region with the greatest market for linked medication delivery systems. Around 3,600 people per year, according to the Asthma and Allergy Foundation of America. Thus, in these situations, connected drug delivery systems seem to be advantageous for the enhancement of patient adherence to the drugs recommended by doctors, thus boosting the regional market.

The Asia Pacific region is predicted to see the quickest growth during the forecast period due to the higher incidence of chronic illnesses and the availability of a large patient population base. The expansion of the region is also anticipated to be fueled by the expanding number of businesses and initiatives launched by them. For instance, the public business Adherium, which has its headquarters in New Zealand, focuses on creating solutions for monitoring system, data management, and patient adherence in the respiratory industry.

News-

Aptar Pharma Launches HeroTracker Sense

On February 8^th, 2022; Aptar Pharma announced the launch of HeroTracker Sense, a breakthrough digital respiratory healthcare system that transforms a typical metered dosage inhaler into a smart linked healthcare system. Aptar Pharma is a global leader in medication delivery devices, services, and active material science solutions.

Jabil Healthcare Announces the Launch of the Qfinity

On May 18^th, 2022; A platform named QfinityTM autoinjector was introduced by Jabil Healthcare, a significant international provider of healthcare manufacturing solutions. When compared to other options on the market, this platform offers a reusable and integrated solution for subcutaneous (SC) medication self-administration at a reasonable cost.

Nemera inaugurated a new facility in Lyon

On September 19^th, 2022; Nemera has opened a new facility in Lyon, France, which will serve as the company's current European headquarters and innovation hub.

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2022 - 2028
Market Size in 2021:	USD 4.63 Billion
Base year considered	2020
Forecast Period CAGR %:	50.21%
Market Size Expected in 2028:	USD 7.99 Billion
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	Novo Nordisk A/S; Teva Respiratory, LLC; Medtronic; Phillips-Medisize, LLC; Tandem Diabetes Care, Inc.; Adherium Limited; Propeller health; Biocorp; Ypsomed AG; Aptar Pharma, and others.
Segments Covered	By Device Type, By Application, By Technology, By End-Use
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa